{"id":5657,"date":"2014-10-30T08:00:00","date_gmt":"2014-10-30T08:00:00","guid":{"rendered":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/jdrf-schrijft-geschiedenis\/"},"modified":"2024-09-23T11:22:41","modified_gmt":"2024-09-23T11:22:41","slug":"jdrf-schrijft-geschiedenis","status":"publish","type":"post","link":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/jdrf-schrijft-geschiedenis\/","title":{"rendered":"Breakthrough T1D schrijft geschiedenis"},"content":{"rendered":"<div class=\"postdetails\">\n<div class=\"entry\">Gisteren was een historische dag voor mensen met Type 1 Diabetes (T1D). Voor het eerst is het ViaCyte inkapseling systeem in een mens geplaatst en zijn de klinische testen dus officieel begonnen. ViaCyte ontwikkelt dit systeem met financi\u00eble steun van Breakthrough T1D. <\/div>\n<div class=\"entry\"> <\/div>\n<div class=\"entry\">\n<p>De therapie van ViaCyte is gebaseerd op stamcellen die via een speciaal afgiftesystee<span class=\"text_exposed_show\">m insuline kunnen afgeven. Ook ontwikkelde ViaCyte het afgiftesysteem, genaamd Encaptra. <\/span><\/p>\n<div class=\"text_exposed_show\">\n<p>Als VC-01 en Encaptra door alle testen heenkomen, zou dat in de toekomst betekenen dat mensen met Type 1 Diabetes (T1D) niet langer afhankelijk zijn van externe insuline. Het Encaptra afgiftesysteem kan dan ge\u00efmplanteerd worden in het lichaam, waarna de VC-01 therapie insuline afgeeft wanneer nodig. Dit is een stap op weg naar een volledige genezing van Type 1 Diabetes.<\/p>\n<p>Meer weten over inkapseling? <a href=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/inkapseling\/\">Kijk hier<\/a>.<\/p>\n<p>Meer info over ViaCyte? <a href=\"http:\/\/www.marketwatch.com\/story\/viacyte-inc-announces-fda-acceptance-of-ind-to-commence-clinical-trial-of-vc-01-candidate-cell-replacement-therapy-for-type-1-diabetes-2014-08-19\">Kijk hier<\/a> (Engelstalig)<\/p>\n<p><div class=\"resp-container\"><\/div><\/p>\n<\/div>\n<\/div>\n<\/div>","protected":false,"raw":""},"excerpt":{"rendered":"<p>Gisteren was een historische dag voor mensen met Type 1 Diabetes (T1D). Voor het eerst is het ViaCyte inkapseling systeem in een mens geplaatst en zijn de klinische testen dus officieel begonnen. ViaCyte ontwikkelt dit systeem met financi\u00eble steun van Breakthrough T1D. De therapie van ViaCyte is gebaseerd op stamcellen die via een speciaal afgiftesysteem [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[184],"tags":[],"class_list":["post-5657","post","type-post","status-publish","format-standard","hentry","category-archief"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Breakthrough T1D schrijft geschiedenis - Breakthrough T1D<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/jdrf-schrijft-geschiedenis\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Breakthrough T1D schrijft geschiedenis - Breakthrough T1D\" \/>\n<meta property=\"og:description\" content=\"Gisteren was een historische dag voor mensen met Type 1 Diabetes (T1D). Voor het eerst is het ViaCyte inkapseling systeem in een mens geplaatst en zijn de klinische testen dus officieel begonnen. ViaCyte ontwikkelt dit systeem met financi\u00eble steun van Breakthrough T1D. De therapie van ViaCyte is gebaseerd op stamcellen die via een speciaal afgiftesysteem [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/jdrf-schrijft-geschiedenis\/\" \/>\n<meta property=\"og:site_name\" content=\"Breakthrough T1D\" \/>\n<meta property=\"article:published_time\" content=\"2014-10-30T08:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-23T11:22:41+00:00\" \/>\n<meta name=\"author\" content=\"ylt-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschreven door\" \/>\n\t<meta name=\"twitter:data1\" content=\"ylt-admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/jdrf-schrijft-geschiedenis\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/jdrf-schrijft-geschiedenis\/\"},\"author\":{\"name\":\"ylt-admin\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\"},\"headline\":\"Breakthrough T1D schrijft geschiedenis\",\"datePublished\":\"2014-10-30T08:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/jdrf-schrijft-geschiedenis\/\"},\"wordCount\":145,\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"articleSection\":[\"Archief\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/jdrf-schrijft-geschiedenis\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/jdrf-schrijft-geschiedenis\/\",\"name\":\"Breakthrough T1D schrijft geschiedenis - Breakthrough T1D\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\"},\"datePublished\":\"2014-10-30T08:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/jdrf-schrijft-geschiedenis\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/jdrf-schrijft-geschiedenis\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/jdrf-schrijft-geschiedenis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/breakthrought1d.eu\/nl\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Breakthrough T1D schrijft geschiedenis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"name\":\"Breakthrough T1D\",\"description\":\"Wij zetten ons in voor een toekomst zonder T1D\",\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\",\"name\":\"Breakthrough T1D\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"contentUrl\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"width\":330,\"height\":141,\"caption\":\"Breakthrough T1D\"},\"image\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\",\"name\":\"ylt-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"caption\":\"ylt-admin\"},\"sameAs\":[\"https:\/\/87.250.144.92\"],\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Breakthrough T1D schrijft geschiedenis - Breakthrough T1D","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/jdrf-schrijft-geschiedenis\/","og_locale":"nl_NL","og_type":"article","og_title":"Breakthrough T1D schrijft geschiedenis - Breakthrough T1D","og_description":"Gisteren was een historische dag voor mensen met Type 1 Diabetes (T1D). Voor het eerst is het ViaCyte inkapseling systeem in een mens geplaatst en zijn de klinische testen dus officieel begonnen. ViaCyte ontwikkelt dit systeem met financi\u00eble steun van Breakthrough T1D. De therapie van ViaCyte is gebaseerd op stamcellen die via een speciaal afgiftesysteem [&hellip;]","og_url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/jdrf-schrijft-geschiedenis\/","og_site_name":"Breakthrough T1D","article_published_time":"2014-10-30T08:00:00+00:00","article_modified_time":"2024-09-23T11:22:41+00:00","author":"ylt-admin","twitter_card":"summary_large_image","twitter_misc":{"Geschreven door":"ylt-admin","Geschatte leestijd":"1 minuut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/jdrf-schrijft-geschiedenis\/#article","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/jdrf-schrijft-geschiedenis\/"},"author":{"name":"ylt-admin","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6"},"headline":"Breakthrough T1D schrijft geschiedenis","datePublished":"2014-10-30T08:00:00+00:00","dateModified":"2024-09-23T11:22:41+00:00","mainEntityOfPage":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/jdrf-schrijft-geschiedenis\/"},"wordCount":145,"publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"articleSection":["Archief"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/jdrf-schrijft-geschiedenis\/","url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/jdrf-schrijft-geschiedenis\/","name":"Breakthrough T1D schrijft geschiedenis - Breakthrough T1D","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#website"},"datePublished":"2014-10-30T08:00:00+00:00","dateModified":"2024-09-23T11:22:41+00:00","breadcrumb":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/jdrf-schrijft-geschiedenis\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/breakthrought1d.eu\/nl\/nieuws\/jdrf-schrijft-geschiedenis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/jdrf-schrijft-geschiedenis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/breakthrought1d.eu\/nl\/"},{"@type":"ListItem","position":2,"name":"Breakthrough T1D schrijft geschiedenis"}]},{"@type":"WebSite","@id":"https:\/\/breakthrought1d.eu\/nl\/#website","url":"https:\/\/breakthrought1d.eu\/nl\/","name":"Breakthrough T1D","description":"Wij zetten ons in voor een toekomst zonder T1D","publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/breakthrought1d.eu\/nl\/#organization","name":"Breakthrough T1D","url":"https:\/\/breakthrought1d.eu\/nl\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/","url":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","contentUrl":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","width":330,"height":141,"caption":"Breakthrough T1D"},"image":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6","name":"ylt-admin","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","caption":"ylt-admin"},"sameAs":["https:\/\/87.250.144.92"],"url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/"}]}},"_links":{"self":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/comments?post=5657"}],"version-history":[{"count":5,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5657\/revisions"}],"predecessor-version":[{"id":8943,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5657\/revisions\/8943"}],"wp:attachment":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/media?parent=5657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/categories?post=5657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/tags?post=5657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}